North Central Cancer Treatment Group/Alliance trial N08CA - The use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study

Cancer

Volumn 120, Issue 12, 2014, Pages 1890-1897

  Leal, Alexis D ^a   Qin, Rui ^a   Atherton, Pamela J ^a   Haluska, Paul ^a   Behrens, Robert J ^b   Tiber, Charles H ^c   Watanaboonyakhet, Patanit ^d   Weiss, Matthias ^e   Adams, Paul T ^f   Dockter, Travis J ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b Iowa Oncology Research Association Community Clinical Oncology Program   (United States)

^c Medical College of Wisconsin   (United States)

^d Trinity Cancer Care Center   (United States)

^e MARSHFIELD CLINIC   (United States)

^f Michigan Cancer Research Consortium   (United States)

Author keywords

carboplatin; chemotherapy induced peripheral neuropathy; glutathione; paclitaxel; prevention

Indexed keywords

CARBOPLATIN; GLUTATHIONE; PACLITAXEL; PLACEBO;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TIME TO TREATMENT; TREATMENT DURATION;

CARBOPLATIN; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; GLUTATHIONE; PACLITAXEL; PREVENTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOUBLE-BLIND METHOD; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBOS;

EID: 84902212165     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28654     Document Type: Article

References (54)

1. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002; 98: 195-203.
2. Polomano RC, Bennett GJ,. Chemotherapy-evoked painful peripheral neuropathy. Pain Med. 2001; 2: 8-14.
3. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ,. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003; 63: 1549-1563.
4. Chaudhary UB, Haldas JR,. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003; 63: 1565-1577.
5. Flatters SJ, Bennett GJ,. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004; 109: 150-161.
6. Ocean AJ, Vahdat LT,. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004; 12: 619-625.
7. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Oncol. 1992; 10: 795-803.
8. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D,. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992; 84: 364-371.
9. Cavaletti G, Minoia C, Schieppati M, Tredici G,. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys. 1994; 29: 771-776.
10. Bogliun G, Marzorati L, Cavaletti G, Frattola L,. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Ital J Neurol Sci. 1992; 13: 643-647.
11. Colombo N, Bini S, Miceli D, et al. Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer. 1995; 5: 81-86.
12. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G,. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995; 13: 26-32.
13. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002; 20: 3478-3483.
14. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L,. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs. 2009; 20: 396-402.
15. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997; 8: 569-573.
16. Lin PC, Lee MY, Wang WS, et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer. 2006; 14: 484-487.
17. Pereira CF, Oliveira CR,. Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+ homeostasis. Neurosci Res. 2000; 37: 227-236.
18. Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011; 29: 1472-1478.
19. Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012; 118: 5171-5178.
20. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001; 19: 1809-1817.
21. Pocock SJ, Simon R,. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975; 31: 103-115.
22. Altman D,. Practical Statistics for Medical Research. London, United Kingdom: Chapman & Hall; 1991.
23. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
24. Cox DR,. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187-220.
25. Diggle P, Heagerty P, Liang K-Y, Zeger SL,. Analysis of Longitudinal Data. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2002.
26. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309: 1359-1367.
27. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance) [published online ahead of print December 2, 2013]. J Clin Oncol. DOI:10.1200/JCO.2013.52. 0536.
28. Kottscade LA, Sloan JA, Mazurezek MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL,. The use of vitamin E for the prevention of chemotherapy-induced peripheral neurpathy: results of a randomized phase III clinical trial. Support Care Cancer 2011; 19: 1769-1777. PMID:20936417.
29. Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013; 31: 2627-2633.
30. Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A,. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997; 67: 172-177.
31. Koeppen S, Verstappen CC, Korte R, et al. Lack of neuroprotection by an ACTH(4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. J Cancer Res Clin Oncol. 2004; 130: 153-160.
32. van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990; 322: 89-94.
33. van Gerven JM, Hovestadt A, Moll JW, et al. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol. 1994; 241: 432-435.
34. Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ,. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol. 1992; 239: 143-146.
35. van Kooten B, van Diemen HA, Groenhout KM, et al. A pilot study on the influence of a corticotropin (4-9) analogue on vinca alkaloid-induced neuropathy. Arch Neurol. 1992; 49: 1027-1031.
36. Boyette-Davis J, Xin W, Zhang H, Dougherty PM,. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011; 152: 308-313.
37. Liu CC, Lu N, Cui Y, et al. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats [serial online]. Mol Pain. 2010; 6: 76.
38. Zhang H, Yoon SY, Dougherty PM,. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of paclitaxel-induced painful neuropathy. J Pain. 2012; 13: 293-303.
39. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM,. The promise of minocycline in neurology. Lancet Neurol. 2004; 3: 744-751.
40. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007; 69: 1404-1410.
41. Cho IH, Chung YM, Park CK, et al. Systemic administration of minocycline inhibits formalin-induced inflammatory pain in rat. Brain Res. 2006; 1072: 208-214.
42. LeBlanc BW, Zerah ML, Kadasi LM, Chai N, Saab CY,. Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatic neuropathy. Neurosci Lett. 2011; 498: 138-142.
43. Ledeboer A, Sloane EM, Milligan ED, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005; 115: 71-83.
44. Marchand F, Tsantoulas C, Singh D, et al. Effects of etanercept and minocycline in a rat model of spinal cord injury. Eur J Pain. 2009; 13: 673-681.
45. Mika J, Rojewska E, Makuch W, Przewlocka B,. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience. 2010; 165: 1420-1428.
46. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK,. Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol. 2011; 661: 15-21.
47. Padi SS, Kulkarni SK,. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol. 2008; 601: 79-87.
48. Raghavendra V, Tanga F, DeLeo JA,. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003; 306: 624-630.
49. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci. 2004; 24: 2182-2190.
50. Mei XP, Xu H, Xie C, et al. Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain. Neurosci Res. 2011; 70: 305-312.
51. Kim TH, Kim HI, Kim J, Park M, Song JH,. Effects of minocycline on Na+ currents in rat dorsal root ganglion neurons. Brain Res. 2011; 1370: 34-42.
52. Cata JP, Weng HR, Dougherty PM,. The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res. 2008; 1229: 100-110.
53. Casha S, Zygun D, McGowan D, Yong VW, Hurlbert JR,. Neuroprotection with minocycline after spinal cord injury: results of a double blind, randomized, controlled pilot study: 929. Neurosurgery. 2009; 65: 410-411.
54. Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012; 23: 200-205.